Pharma BD Deal Intelligence
A criticized $15.6B all-cash bet that outlasted its skeptics: MedImmune handed AstraZeneca Synagis, FluMist, and a 45-project biologics pipeline the market initially dismissed as overpaid. A decade on, that platform underpinned AstraZeneca's biologics transformation and Imfinzi's rise.
Criticized as overpriced but eventually enabled AstraZeneca biologics transformation
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
This acquisition represents a transformational step to deliver our biologics strategy sooner than anticipated. It creates a leading fully integrated biologics…
AstraZeneca to buy MedImmune for $15.6 billion.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
AstraZeneca acquired MedImmune for approximately $15.6 billion ($58 per share in cash), gaining a leading biologics and vaccines platform including blockbuster Synagis, FluMist, and a 45-project pipeline to transform AstraZeneca into an integrated biologics company.
$1.1B Synagis Revenue (2007)
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection in infants and young children, with nearly all children infected by age 2. RSV is the most common cause of bronchiolitis and pneumonia in children under 1 year and the leading cause of US infant hospitalization, with an estimated 57,000-80,000 infant hospitalizations each fall-winter season. Premature infants, infants with congenital heart disease, and those with chronic lung disease face the highest risk of severe disease.
AstraZeneca's $15.6B acquisition of MedImmune was its largest deal ever, transforming AZ from a small-molecule company into an integrated biologics player. Synagis provided immediate revenue, while MedImmune's 45-project pipeline and biologics manufacturing platform delivered long-term strategic value.
AstraZeneca PLC closes acquisition/merger of MedImmune Inc. for $15.6B, establishing strategic position and initiating integration.
AstraZeneca paid $15.6B for MedImmune in a criticized deal that took a decade to justify but ultimately enabled Imfinzi and broader biologics capability.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / MedImmune Inc. (this deal) | 2007 | $15.6B | 82 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / CinCor Pharma Inc. | 2023 | $1.8B | 78 |
← Browse all deals · How we score deals
More: 2007 deals · AstraZeneca PLC deals · Infectious Disease deals